The top 15 blockbuster patent expirations coming this decade

 

Looking out over the next decade, some of the biggest drugs in the industry will tumble off the patent cliff, putting pharma giants in the hot seat as investors clamor for their next blockbuster.

The biggest names set to face generic pressure in the coming years include the top four of the industry’s best-selling drugs in 2020: Humira, Keytruda, Revlimid and Eliquis. 

In all, nine of the industry’s top 20 drugs by sales are set to lose exclusivity over the coming years, Moody’s analysts wrote in a recent report.

To be sure, it’s not easy to predict exactly when competition will start heating up since there may be numerous patents protecting these medicines, said Moody’s Mike Levesque, the leading author of the report. It’s also unclear whether some companies may be able to evade generic competition through court, or when imitators will score regulatory approval. 

Mas